Desiree Granados Quick Summary: Tirzepatide and semaglutide both support weight loss through incretin pathways, with tirzepatide targeting both GIP and GLP-1 receptors for potentially greater weight reduction in clinical studies, while semaglutide focuses on GLP-1 with wide usage and well-documented metabolic benefits
This dual action allows Tirzepatide to lower blood glucose levels, enhance insulin sensitivity, promote satiety, and accelerate weight loss
This present-focused therapy helps individuals attain safety from traumaincluding post-traumatic stress disorder and substance misuseby emphasizing coping skills, grounding techniques, and education
The most frequently reported adverse events were nausea, diarrhea, vomiting, constipation, abdominal pain, headache and fatigue
Heckman-Stoddard, B